Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 2 |
DNA vaccine | 1 |
Genetically engineered subunit vaccine | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV S protein x SARS-CoV-2 S protein | 1 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism SARS-CoV S protein inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 May 2021 |
Sponsor / Collaborator |
Start Date30 Nov 2020 |
Sponsor / Collaborator |
Start Date16 Oct 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant respiratory syncytial vrus vaccine(Beijing Advaccine Biotechnology Co., Ltd.) | Respiratory Syncytial Virus Infections More | Phase 2 |
pAD1016 ( SARS-CoV S protein x SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
INO-4800 ( SARS-CoV-2 S protein ) | Severe Acute Respiratory Syndrome More | Discontinued |